2029 Marketing Regulations Trials 
Agency IQ
JULY 22, 2024
Updated EUDAMED roadmap projects mandatory use of some processes as early as December 2025 The new EUDAMED roadmap includes updates accounting for the recent amendments to the European medical device and diagnostics regulations, which allow for a phased rollout of the different functional modules of the database.
Drug Discovery World
MAY 15, 2024
Marketed anti-VEGF therapeutics effectively neutralise retinal VEGF levels and reduce both vascular leak and consequential oedema, resulting in a temporary improvement in vision, but do nothing to address the underlying pathology – capillary drop-out 5. million by 2029, according to GlobalData. In 2019 there were >14.2
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Agency IQ
JANUARY 26, 2024
regulators considered the highest-risk IVD devices, and these and devices for self-test by the patient required Notified Body oversight. The IVDR originally gave stakeholders 5 years to comply with the regulation (May 26, 2022). The directive used a list-based system – List A and List B outlined what E.U. Once the E.U.
Agency IQ
FEBRUARY 2, 2024
Diagnostics landscape analysis: Key issues and a look ahead at 2024 Diagnostic regulation in the U.S. Following significant policy proposals in recent years, 2024 is gearing up to be a profoundly impactful year for diagnostics developers and the policymakers who regulate them. is a constantly evolving topic. In the U.S., In the E.U.,
Drug Discovery World
JULY 26, 2024
While the shadow of the pandemic recedes, its effects linger in the form of a market correction and an evolving healthcare landscape. The strategy is aimed at keeping the sector competitive in a country that has recently been struggling to maintain relevance in the global medical device and clinical trials scenes.
Expert insights. Personalized for you.
40 
Let's personalize your content